200, Stuart St

Boston,

MA,

USA,

ZIP: 02116

Phone: +1 617 455 4188

The 7th Microbiome Movement - Drug Development Summit returns to Boston at a pivotal time. As the microbiome therapeutic space matures, with more indications being pursued and more companies conducting trials, the focus of this event - now in its 7th year - is evolving to showcase these new studies. With this progress however comes new challenges, and we're excited to once again be uniting over 300 microbiome pioneers to work towards overcoming these challenges and moving the whole industry closer to commercial approval. 

Continuing to unite the most forward-thinking researchers from the biopharmaceutical industry, our unrivaled program will uncover microbiome functionality and mechanisms, decipher translation issues and advance clinical development, overcome the key GMP manufacturing and scale-up challenges, whilst also discovering and applying microbiome biomarkers for improved clinical outcomes.

This event  is the most comprehensive forum for microbiome drug developers and the perfect opportunity for the industry to take a collaborative approach to close the clinical gap, discover the next generation of microbiome-based therapeutics, and establish new partnerships to accelerate your research.

Early booking and group discounts are available for this event. Bring your team to cover all bases and maximize your learning opportunity through our tracked sessions. Email [email protected] to enquire about discounts. 

URLs:
Tickets:  https://go.evvnt.com/1056009-2?pid=1052 
Brochure:  https://go.evvnt.com/1056009-3?pid=1052 

Prices:
Drug Developer Pricing - Conference + Focus Day: USD 4696.00,
Drug Developer Pricing - Conference + Workshop Day: USD 4696.00,
Drug Developer Pricing - Conference Only: USD 2899.00,
Academic and Not-For-Profit Pricing - Conference + Focus Day: USD 3996.00,
Academic and Not-For-Profit Pricing - Conference + Workshop Day: USD 3996.00,
Academic and Not-For-Profit Pricing - Conference Only: USD 2499.00,
Solution and Service Provider - Conference + Focus Day: USD 5596.00,
Solution and Service Provider - Conference + Workshop Day: USD 5596.00,
Solution and Service Provider - Conference Only: USD 3499.00

Assaf Oron, Chief Business Officer, BiomX, Gerard Honig Director, Research Innovation, Crohn's and Colitis Foundation, Sonia Timberlake, VP Research, Finch Therapeutics, Stewart Campbell, CEO, Axial Therapeutics, Ken Blount, VP Microbiome Research and CSO, Rebiotix, a Ferring Company, Mark Smith, CEO, Finch Therapeutics, Morten Isaksen, CEO, Bio-Me AS, Travis Whitfill, Co-Founder, Executive Director of Advanced Technology Chair, Scientific Advisory Board, Azitra, Brian Klein, CEO, BrickBuilt Therapeutics, Paul Carlson, Principal Investigator, FDA, Sean Gibbons, Assistant Professor, Institute Systems Biology, Yvonne Nyavor, Principal Scientist, Microbiome, Boston Analytical, Bharat Dixit VP, Biopharmaceutical Development and Manufacturing, Artugen Therapeutics, Fyza Shaik, Instructor, John Hopkins Medical Center, Louis Cohen, Assistant Professor, Icahn School of Medicine, Mount Sinai, Sandrine Miller Montgomery, CEO, Micronoma, David Ege, CTO, Seres Therapeutics, Denise Kelly, Investment Advisor, Seventure Partners, Jeanette Mucha, CEO, SciBac, Nikole Kimes, Founder and CEO, Siolta Therapeutics, Caitlin SL Parello, Senior Scientist II, Associate Director of in vitro Services, Biomodels, Felix Faupel, Chief Commerical Officer, BacThera, Mark Charbonneau, Head, Quantitative Biology, Synlogic, Peter McCaffrey, CRO, VastBiome, Antonio DiGiandomenico, Director of Microbiome Discovery, AstraZeneca, Dirk Gevers, Global Head Janssen Human Microbiome Institute, Janssen Research and Development, Jessica Schneider, Director of Gastroenterology, Takeda, Xin Guo, Principle Scientist, Merck, John Hambor, Director, Research Beyond Boarders, Boehringer Ingleheim, Nancy Dubois, Associate Director, Local Safety Officer US Region + Senior Manager, Risk Evaluation and Mitigation Strategies, Alexion/AstraZeneca Rare Disease, Serge Sagodira, Director Licensing Transactions, Debiopharm, Will DeLoache, Co-Founder and CEO, Novome Biotechnologies, Daniel van de Lelie, CEO, Gusto Global LLC, Kareem Barghout, Co-Founder and CEO, Vast Biome, Paul Miller, CSO, Artizan Biosciences, Inc., Ron Carter, CMO, Microbiotica, Afif Ghannoum, CEO, Biohm Health, Antonio Gomes Principal Scientist Xbiome, Daniel Couto COO Vedanta, Mark Carbonneau Sr. Director, Head of Translational Science Synlogictx, Taku Nakahara Co-Founder and CEO Metagen Therapeutics, Inc., Tanya Yatsuneko Chief Of Staff and head of Academic Collaborations Bristol Myers Squibb, Wei-Kai Wu Research Physician, Department of Medical Research, Division of Gastroenterology and Hepatology, Department of Internal Medicine National Taiwan University Hospital, Department of Internal Medicine, Yoshinori Hamaji Associate Scientific Director, Microbial Development Takeda, Eran Kosover Chief Business Officer MyBiotics, James Mcllroy CEO Enterobiotix, Mary Ruisi Vice President Clinical Research Vedanta, Sophie Durand CEO Stellate Therapeutics, Bryan Jones Senior Director, Scientific Affairs Gelesis, Joe Trebley CEO Sciotio Biosciences, Magali Cordaillant-Simons Scientific and Regulatory Affairs Director PRI, Vivek Lal Founder and CEO Alveolus Bio and ResBiotic, Alessio Fando Professor and Director of the Mucosal Immunology and Biology Research Center, Massachusetts General Hospital, Christian Furlan Freguia Vice President of Research Rise Therapeutics, Elran Haber CEO Biomica Ltd., Romain Daillere Head of Preclinical Research and Co-founder EverImmune, Elizabeth Halvorsen PhD Director of Host Biology Seres Therapeutics, Giulio Pasenetti Saunders Family Chair and Professor of Neurology Icahn School of Medicine at Mount Sinai, Lu Jing Research Professional University of Chicago Medicine, Nikhil Sharma CEO BioCorteX, Barbara McGovern MD Senior Advisor Medical Affairs and Clinical Development Seres Therapeutics, Christopher Ford Exec. Director Microbiome Sciences Seres Therapeutics, Jeffrey Heiser Senior Director, Head of Process Development and Analytical Development Arranta Bio, Shahram Lavasani Founder and CEO ImmuneBiotech AB, Amanda Prince Senior Scientist, Immunology Vedanta Biosciences, Inc., Shuo Han Postdoctoral Research Fellow in Microbiology and Immunology Stanford University School of Medicine, Tue Hodal Chief Manufacturing Officer Bacthera, Yakov Ginzburg RandD manager, Microbiome MetabolomicsTechnologies Millipore Sigma, Bharat Dixit VP, Biopharmaceutical Development and Manufacturing Artugen Therapeutics, Maireadh Pedersen CEO SGS Quay Pharma, Nick Conley, PhD VP of Technology Locus Biosciences, Inc., Stacy Burns-Guydish President List Labs, Brian Ingram Director, Discovery and Translational Sciences Metabolon, Johan Van Hylckama Vlieg CSO Kaleido Boiscience, Josh Narrow Project Manager The Conafay Group, Tina Papagiannopoulos Associate Foley Hoag-LLP, Eric Shaff Chief Executive Officer Seres Therapeutics, Matthew Henn PhD Chief Scientific Officer Seres Therapeutics, Natalie D’Amore PhD Exec. Director External Innovation Seres Therapeutics, Páraic Ó Cuív Lead of Live Biotherapeutics Microba, Manoj Dadlani CEO CosmosID, Inc., Mo Langhi Director, Business Development CosmosID, Inc.